Y-mAbs Therapeutics Statistics
Total Valuation
YMAB has a market cap or net worth of $391.22 million. The enterprise value is $332.06 million.
| Market Cap | 391.22M |
| Enterprise Value | 332.06M |
Important Dates
The last earnings date was Friday, November 7, 2025, before market open.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
YMAB has 45.44 million shares outstanding. The number of shares has increased by 2.79% in one year.
| Current Share Class | 45.44M |
| Shares Outstanding | 45.44M |
| Shares Change (YoY) | +2.79% |
| Shares Change (QoQ) | +0.47% |
| Owned by Insiders (%) | 1.72% |
| Owned by Institutions (%) | 39.89% |
| Float | 18.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.54 |
| Forward PS | 4.43 |
| PB Ratio | 4.47 |
| P/TBV Ratio | 4.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.00, with a Debt / Equity ratio of 0.04.
| Current Ratio | 4.00 |
| Quick Ratio | 3.40 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -24.31% and return on invested capital (ROIC) is -12.09%.
| Return on Equity (ROE) | -24.31% |
| Return on Assets (ROA) | -8.67% |
| Return on Invested Capital (ROIC) | -12.09% |
| Return on Capital Employed (ROCE) | -19.21% |
| Revenue Per Employee | $821,010 |
| Profits Per Employee | -$213,692 |
| Employee Count | 104 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 1.73 |
Taxes
| Income Tax | -394,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.34% in the last 52 weeks. The beta is 0.53, so YMAB's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | -37.34% |
| 50-Day Moving Average | 6.93 |
| 200-Day Moving Average | 6.11 |
| Relative Strength Index (RSI) | 81.20 |
| Average Volume (20 Days) | 723,782 |
Short Selling Information
The latest short interest is 1.85 million, so 4.08% of the outstanding shares have been sold short.
| Short Interest | 1.85M |
| Short Previous Month | 1.66M |
| Short % of Shares Out | 4.08% |
| Short % of Float | 9.80% |
| Short Ratio (days to cover) | 1.00 |
Income Statement
In the last 12 months, YMAB had revenue of $85.39 million and -$22.22 million in losses. Loss per share was -$0.49.
| Revenue | 85.39M |
| Gross Profit | 69.58M |
| Operating Income | -18.11M |
| Pretax Income | -23.97M |
| Net Income | -22.22M |
| EBITDA | -17.77M |
| EBIT | -18.11M |
| Loss Per Share | -$0.49 |
Balance Sheet
The company has $62.29 million in cash and $3.12 million in debt, giving a net cash position of $59.17 million or $1.30 per share.
| Cash & Cash Equivalents | 62.29M |
| Total Debt | 3.12M |
| Net Cash | 59.17M |
| Net Cash Per Share | $1.30 |
| Equity (Book Value) | 87.49M |
| Book Value Per Share | 1.93 |
| Working Capital | 68.84M |
Cash Flow
In the last 12 months, operating cash flow was -$17.80 million and capital expenditures -$127,000, giving a free cash flow of -$17.92 million.
| Operating Cash Flow | -17.80M |
| Capital Expenditures | -127,000 |
| Free Cash Flow | -17.92M |
| FCF Per Share | -$0.39 |
Margins
Gross margin is 81.49%, with operating and profit margins of -21.21% and -26.03%.
| Gross Margin | 81.49% |
| Operating Margin | -21.21% |
| Pretax Margin | -26.49% |
| Profit Margin | -26.03% |
| EBITDA Margin | -20.81% |
| EBIT Margin | -21.21% |
| FCF Margin | n/a |
Dividends & Yields
YMAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.79% |
| Shareholder Yield | -2.79% |
| Earnings Yield | -5.68% |
| FCF Yield | -4.58% |
Analyst Forecast
The average price target for YMAB is $13.91, which is 61.56% higher than the current price. The consensus rating is "Buy".
| Price Target | $13.91 |
| Price Target Difference | 61.56% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 18.56% |
| EPS Growth Forecast (5Y) | -16.41% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
YMAB has an Altman Z-Score of 3 and a Piotroski F-Score of 3.
| Altman Z-Score | 3 |
| Piotroski F-Score | 3 |